IQIRVO

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Jun 10, 2024

   2 yr 1 mo ago

2. Today

3. Exclusivity ends · NCE

   New chemical entity exclusivity (5 years)

   Jun 10, 2029

   in 3 yr

4. Exclusivity ends · ODE-486

   Orphan-drug exclusivity (7 years)

   Jun 10, 2031

   in 5 yr 1 mo

5. Patent 11185519 expires

   Listed method-of-use patent (U-3955) expiration.

   Mar 30, 2037

   in 10 yr 11 mo

6. Patent 11331292 expires

   Listed method-of-use patent (U-1854) expiration.

   Mar 30, 2037

   in 10 yr 11 mo

7. Patent 11850223 expires

   Listed method-of-use patent (U-1854) expiration.

   Mar 30, 2037

   in 10 yr 11 mo

8. Patent 11857523 expires

   Listed method-of-use patent (U-3955) expiration.

   Mar 30, 2037

   in 10 yr 11 mo

9. Patent 12233038 expires

   Listed method-of-use patent (U-1854) expiration.

   Mar 30, 2037

   in 10 yr 11 mo

10. Patent 12295927 expires

    Listed method-of-use patent (U-1854) expiration.

    Mar 30, 2037

    in 10 yr 11 mo

11. Patent 12295928 expires

    Listed method-of-use patent (U-1854) expiration.

    Mar 30, 2037

    in 10 yr 11 mo

12. Patent 12310935 expires

    Listed method-of-use patent (U-1854) expiration.

    Mar 30, 2037

    in 10 yr 11 mo

13. Patent 12589086 expires

    Listed method-of-use patent (U-4473) expiration.

    Mar 30, 2037

    in 10 yr 11 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (2)

• NCENew chemical entity exclusivity (5 years)

  Jun 10, 2029

  in 3 yr

• ODE-486Orphan-drug exclusivity (7 years)

  Jun 10, 2031

  in 5 yr 1 mo

Listed patents (9)